Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02519777 · ClinicalTrials.gov registry record · Phase 4
Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)
A Phase 4 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 4
- Development phase
- 191
- Enrollment target
NCT02519777 is a Phase 4 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 191 participants.
The verdict
NCT02519777, a Phase 4 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 191 participants
- Enrollment target
Study Summary
People infected with HIV often have cognitive dysfunction even if they are on antiretroviral therapy (ART) and have undetectable viral loads. The study evaluated if the addition of maraviroc (MVC) and dolutegravir (DTG) (which are two antiretroviral \[ARV\] medications) to participants' existing ART regimens improved participants' neurocognitive performance.
Interventions
- DRUG Dolutegravir (DTG)
- DRUG Placebo for maraviroc (MVC)
- DRUG Placebo for dolutegravir (DTG)
- DRUG Maraviroc (MVC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2016-04-21 |
| Est. Completion | 2021-01-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02519777
The ClinicalTrials.gov registry entry for NCT02519777 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dolutegravir (DTG) is the first listed.
NCT02519777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02519777 about?
NCT02519777 is a clinical study titled "Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)". People infected with HIV often have cognitive dysfunction even if they are on antiretroviral therapy (ART) and have undetectable viral loads. The study evaluated if the addition of maraviroc (MVC) and dolutegravir (DTG) (which are two antiretroviral \[ARV\] medications) to participants' existing ART...
What is the current status of trial NCT02519777?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 191 participants. The study started on 2016-04-21. Estimated completion is 2021-01-05.
What interventions are being tested in trial NCT02519777?
The interventions under investigation include: Dolutegravir (DTG) (DRUG), Placebo for maraviroc (MVC) (DRUG), Placebo for dolutegravir (DTG) (DRUG), Maraviroc (MVC) (DRUG).
Who is sponsoring clinical trial NCT02519777?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.